One of our members Reid Millius' and her family have genetic erythromelalgia and have been involved in experiments for NaV1.7 medicines.

Those experiments have now entered the labs of half a dozen biopharmaceutical companies. The hope: development of a new class of medicines that can mimic congenital insensitivity to pain genes and treat families like Millius', and the millions of people living with other forms of chronic pain.

EM expert Dr Stephen Waxman from Yale University gives his plans to develop a new class of medicines. 

Rare genes yield new hope for managing pain without opioids